🛡️ Material News · AGP
AGP Limited has issued a clarification regarding misleading reports about its product Azomax® (Azithromycin) following a government alert concerning counterfeit products. The company asserts that the alert pertains to a fake product and does not affect the quality or regulatory compliance of its genuine offerings.
- AGP Limited addresses misinformation circulating about Azomax® after Prompt Alert No. 97/2026 issued by the Punjab Directorate of Drugs Control.
- The alert specifically identifies a counterfeit product (Batch No. H5332) not manufactured by AGP.
- The company confirms that its genuine Azomax® continues to meet all regulatory standards and is produced in GMP-compliant facilities.
- Azomax® has annual sales exceeding PKR 5 billion, reflecting strong market trust despite the recent negative publicity.
- AGP has implemented multiple anti-counterfeit measures to protect its brand integrity, including advanced security features on packaging.
- The incident has no impact on AGP's manufacturing operations or product quality systems.
- AGP reserves the right to take legal action against those responsible for the counterfeit products and misinformation.
About this brief: prepared automatically by BSL’s research systems from the company’s filing with the exchange. A summary for information, not investment advice — the original filing is the authoritative record.
Original filing (PDF)